Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Onchocerciasis Treatment Market Growth Potential: How Will Market Size Shift Through 2030?
The onchocerciasis treatment market size has experienced robust expansion in recent times. This market is projected to expand from $1.11 billion in 2025 to $1.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to its historical growth include the restricted access to ivermectin and doxycycline in affected areas, a reliance on hospital-centric distribution methods, insufficient public knowledge regarding onchocerciasis management, underdeveloped preventive chemotherapy initiatives, and an over-reliance solely on oral drug forms.
The onchocerciasis treatment market is projected to experience robust expansion over the coming years. Its value is anticipated to reach $1.59 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be attributed to several factors, including the introduction of moxidectin and advanced long-acting formulations, the broadening reach of online and retail pharmacy distribution channels, the creation of novel combination therapies, increased financial support from governments and non-governmental organizations for eradication initiatives, and the implementation of community-focused preventive strategies. Key developments anticipated within this period include the scaling up of mass drug administration (MDA) programs, the formulation of treatments specifically for pediatric use and as fixed-dose combinations, a heightened emphasis on anti-wolbachia therapies, the integration of both oral and injectable treatment protocols, and an increase in community-based and government-backed treatment campaigns.
Get A Free Sample Report With In-Depth Market Insights:
Onchocerciasis Treatment Market Expansion Drivers: What’s Shaping Future Growth?
The growing number of patients experiencing eye-related conditions is expected to boost the onchocerciasis treatment market in the future. Eye-associated issues cover a range of conditions affecting vision and ocular health, including infections, injuries, and chronic diseases like glaucoma or cataracts. This increase in patients with eye problems is primarily attributed to rising screen time and extended use of digital devices. Onchocerciasis treatment assists in preventing and managing vision loss and blindness by eliminating the parasitic infection that causes inflammation and damage to ocular tissues. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that about 20.5 million Americans over the age of 40 suffer from cataracts in at least one eye, accounting for 17.2% of that population. It is projected that nearly 30 million people will develop cataracts by 2028. Consequently, the increasing prevalence of eye-related conditions is fueling growth in the onchocerciasis treatment market. The increasing need for surgical procedures is anticipated to drive the onchocerciasis treatment market forward. Surgical procedures are medical interventions aimed at removing or repairing tissues damaged by disease, often employed when drug treatments are ineffective or when complications pose a threat to long-term health. This rise is fueled by the progression of onchocerciasis in some patients to advanced stages, where surgical intervention becomes essential to prevent permanent damage, such as vision loss or disfigurement. As a result, healthcare providers are expanding surgical services and investing in advanced techniques, thereby stimulating the overall market for onchocerciasis treatment. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional body for board-certified aesthetic plastic surgeons, in 2023, nearly 35 million aesthetic procedures were performed worldwide, representing a 3.4% increase from 2022. The report also highlighted that surgical procedures rose by 5.5%, with more than 15.8 million procedures performed by plastic surgeons. Therefore, the increasing demand for surgical procedures is driving growth in the onchocerciasis treatment market.
Onchocerciasis Treatment Market Segmentation And Category Overview
The onchocerciasis treatment market covered in this report is segmented –
1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin
2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment
3) By Mode Of Administration: Oral, Injectables, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs
Subsegments:
1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations
2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments
3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas
4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs
Onchocerciasis Treatment Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the onchocerciasis treatment market are concentrating on developing innovative antiparasitic medications to enhance treatment effectiveness and shorten its duration. Antiparasitic medications are drugs formulated to eliminate or inhibit parasites, such as worms and protozoa, that cause human infections. For instance, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets, designed to treat river blindness in individuals aged 4 years and older. This approval empowers Ghana to implement community-based mass drug administration programs using moxidectin, which offers superior efficacy and more prolonged effects compared to ivermectin. With this sanction, MDGH seeks to expand access to an effective new onchocerciasis treatment, thereby enabling large-scale community programs in endemic regions.
Onchocerciasis Treatment Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.
View The Full Onchocerciasis Treatment Market Report:
Onchocerciasis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model